AlloVir (NASDAQ:ALVR) Stock Price Up 0.5% – Should You Buy?

AlloVir, Inc. (NASDAQ:ALVR)’s share price was up 0.5% during trading on Friday . The stock traded as high as $10.10 and last traded at $10.05. Approximately 6,842 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 38,106 shares. The stock had previously closed at $10.00.

AlloVir Price Performance

The stock has a market capitalization of $50.52 million, a PE ratio of -0.50 and a beta of 0.65. The company has a 50-day moving average of $10.29 and a two-hundred day moving average of $14.87.

AlloVir (NASDAQ:ALVR) last released its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.22) by $2.30.

Institutional Trading of AlloVir

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC lifted its stake in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,816 shares of the company’s stock after buying an additional 30,072 shares during the period. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent SEC filing. 66.05% of the stock is owned by hedge funds and other institutional investors.

AlloVir Company Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.